N@N

Vikram Purohit Upgraded (AXSM) to Buy and Increased Target to $115 on, Apr 29th, 2024

Vikram Purohit of Morgan Stanley, Upgraded "Axsome Therapeutics, Inc." (AXSM) to Buy and Increased Target from $90 to $115 on, Apr 29th, 2024.

Vikram has made no other calls on AXSM in the last 4 months.

There are 10 other peers that have a rating on AXSM. Out of the 10 peers that are also analyzing AXSM, 0 agree with Vikram's Rating of Hold.

These are the ratings of the 10 analyists that currently disagree with Vikram

---

• Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $107 on, Wednesday, April 10th, 2024
• Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $190 on, Tuesday, April 2nd, 2024
• Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Increased Target to $109 on, Thursday, March 28th, 2024
• Joon Lee of "Truist Securities" Maintained at Strong Buy and Held Target at $150 on, Tuesday, March 26th, 2024
• Leonid Timashev of "RBC Capital" Maintained at Buy with Increased Target to $128 on, Tuesday, March 26th, 2024
• David Hoang of "Citigroup" Maintained at Strong Buy with Increased Target to $127 on, Tuesday, March 26th, 2024
• Joel Beatty of "Baird" Initiated at Buy and Held Target at $108 on, Tuesday, March 19th, 2024
• Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Increased Target to $125 on, Wednesday, February 21st, 2024
• Ashwani Verma of "UBS" Initiated at Strong Buy and Held Target at $111 on, Tuesday, February 6th, 2024
• David Amsellem of "Piper Sandler" Maintained at Buy with Increased Target to $113 on, Tuesday, January 16th, 2024

Contributing Sources

---